keyword
https://read.qxmd.com/read/38344632/role-of-cyclin-dependent-kinase-4-6-in-metastatic-breast-cancer-real-world-data-from-a-tertiary-care-institute-in-eastern-india
#21
JOURNAL ARTICLE
Saroj Kumar Das Majumdar, Sandip Kumar Barik, Ashutosh Pattanaik, Deepak Kumar Das, Dillip Kumar Parida
Introduction CDK4/6 inhibitors currently approved for patients with hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer include palbociclib, ribociclib, and abemaciclib. This study aims to report on the treatment outcomes and real-world data regarding the use of CDK4/6 inhibitors in the treatment of ER+/HER2- metastatic breast cancer at a tertiary care institute in Eastern India. Materials and methods The present study is a retrospective analysis of data from patients with metastatic HR+/HER2- breast cancer who were treated with CDK4/6 inhibitors at a tertiary care institute in Eastern India between 2015 and 2022...
January 2024: Curēus
https://read.qxmd.com/read/38326452/comparative-overall-survival-of-cdk4-6-inhibitors-in-combination-with-endocrine-therapy-in-advanced-breast-cancer
#22
JOURNAL ARTICLE
Coralea Kappel, Mitchell J Elliott, Vikaash Kumar, Michelle B Nadler, Alexandra Desnoyers, Eitan Amir
Individual trials of abemaciclib, palbociclib, and ribociclib show a similar impact on progression-free survival yet differing statistical significance for overall survival (OS). A robust comparative evaluation of OS, safety, and tolerability of the three drugs is warranted. A systematic literature search identified phase 3 randomized clinical trials reporting OS of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy in ER-positive/HER2-negative advanced breast cancer. Trial-level data on OS and common and serious adverse events (AE) were extracted for each drug...
February 7, 2024: Scientific Reports
https://read.qxmd.com/read/38320891/cyclin-dependent-kinase-4-6-inhibitors-as-neoadjuvant-therapy-of-hormone-receptor-positive-her2-negative-early-breast-cancer-what-do-we-know-so-far
#23
REVIEW
Ioanna Ploumaki, Efthymios Triantafyllou, Ioannis-Alexios Koumprentziotis, Konstantinos Karampinos, Konstantinos Drougkas, Ioannis Karavolias, Elias Kotteas
The introduction of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors to the treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer is regarded as one of the greatest achievements of the last decades in breast oncology. To date, palbociclib, abemaciclib and ribociclib are the 3 approved CDK4/6 inhibitors that combined with endocrine therapy are now considered as the standard first-line treatment of metastatic HR+/HER2- breast cancer. The great success of these drugs in the setting of metastatic disease and the need to combat the high risk of recurrence have paved the way for a number of clinical trials to explore the use of CDK4/6 inhibitors in the neoadjuvant treatment of early breast cancer...
January 16, 2024: Clinical Breast Cancer
https://read.qxmd.com/read/38310597/the-efficacy-of-palbociclib-and-ribociclib-in-the-first-line-treatment-of-metastatic-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-in-male-patients-a-turkish-oncology-group-tog-study
#24
JOURNAL ARTICLE
Hasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, Musa Barış Aykan, Mustafa Korkmaz, Selim Yalçın, Teoman Şakalar, Özde Melisa Celayir, Erkan Kayıkçıoğlu, Ferit Aslan, Emre Hafızoğlu, Yunus Emre Altıntaş, Merve Keskinkılıç, Elvin Chalabiyev, Abdussamet Çelebi, Bengü Dursun, Caner Kapar, Miraç Özen, Ömer Acar, Özgecan Dülgar, Engin Kut, Sedat Biter, Fatih Kus, Elvina Almuradova, Atike Pınar Erdoğan, Seray Saray, Deniz Can Güven, Eda Tanrıkulu Şimşek, Necdet Üskent, Yasemin Kemal, Burcu Çakar, Özgür Açıkgöz, Saadettin Kılıçkap, Sercan Aksoy
INTRODUCTION: Male breast cancer, comprising approximately 1% of all breast cancer cases, often leads to the exclusion of male patients as a criterion in clinical trials. While the efficacy of Cyclin-dependent kinases 4 and 6 (CDK 4/6) inhibitors has been established in metastatic hormone receptor-positive (HR +) and human epidermal growth factor receptor 2-negative (HER2 -) breast cancer in women, limited data exist on their effectiveness in male patients. We aimed to evaluate the efficacy and safety of palbociclib or ribociclib in male patients with breast cancer...
February 4, 2024: International Journal of Clinical Oncology
https://read.qxmd.com/read/38302240/flow-cytometry-assisted-quantification-of-cell-cycle-arrest-in-cancer-cells-treated-with-cdk4-6-inhibitors
#25
JOURNAL ARTICLE
Vanessa Klapp, Norma Bloy, Carlos Jiménez-Cortegana, Aitziber Buqué, Giulia Petroni
Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (i.e., palbociclib, abemaciclib, and ribociclib) are well known for their capacity to mediate cytostatic effects by promoting cell cycle arrest in the G1 phase, thus inhibiting cancer cell proliferation. Cytostatic effects induced by CDK4/6 inhibitors can be transient or lead to a permanent state of cell cycle arrest, commonly defined as cellular senescence. Induction of senescence is often associated to metabolic modifications and to the acquisition of a senescence-associated secretory phenotype (SASP) by cancer cells, which in turn can promote or limit antitumor immunity (and thus the efficacy of CDK4/6 inhibitors) depending on SASP components...
2024: Methods in Cell Biology
https://read.qxmd.com/read/38288438/the-adverse-events-of-cdk4-6-inhibitors-for-hr-her2-breast-cancer-an-umbrella-review-of-meta-analyses-of-randomized-controlled-trials
#26
Dongqing Pu, Yue Wu, Debo Xu, Guangxi Shi, Hanhan Chen, Dandan Feng, Mengdi Zhang, Jingwei Li
Background: The clinical selection of three CDK4/6 inhibitors presents a challenging issue, owing to the absence of distinct clinical case characteristics, biomarkers, and their comparable clinical benefits in progression-free survival and overall survival To inform clinical treatment decisions, we conducted a comprehensive evaluation of the adverse events associated with CDK4/6 inhibitors in combination with endocrine therapy for hazard ratio+/HER2-breast cancer. Methods: We searched Cochrane, PubMed, Embase, and Web of Science databases from their inception until 1 August 2022...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38245458/cdk4-6-inhibitors-in-the-treatment-of-metastatic-breast-cancer-focus-on-toxicity-and-safety
#27
REVIEW
Demi Wekking, Matteo Lambertini, Mariele Dessì, Nerina Denaro, Fabio Bardanzellu, Ornella Garrone, Mario Scartozzi, Cinzia Solinas
The development of oral cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib, has revolutionized the treatment landscape for patients with hormone-receptor-positive (HR+) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (BC). When combined with an aromatase inhibitor or fulvestrant, these agents have been approved as first-line therapy in the metastatic setting. Abemaciclib has also gained FDA approval for patients with HR-positive, HER2-negative, node-positive, early BC at high risk of recurrence...
January 13, 2024: Seminars in Oncology
https://read.qxmd.com/read/38244190/use-of-pharmacokinetic-and-pharmacodynamic-data-to-develop-the-cdk4-6-inhibitor-ribociclib-for-patients-with-advanced-breast-cancer
#28
REVIEW
Yan Ji, Hilmar Schiller, Shu Yang, Michelle Quinlan, Christelle Darstein, Felix Huth, Serge Winter, Abhijit Chakraborty
Ribociclib is an orally bioavailable, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor. CDK4/6 inhibition by ribociclib leads to retinoblastoma tumor suppressor protein (Rb) reactivation, thereby restoring Rb-mediated cell cycle arrest. Ribociclib is approved for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor-2-negative (HR+/HER2-) advanced breast cancer (ABC), at the dose of 600 mg once daily (QD) during cycles of 21 days on/7 days off, with optional dose reduction to 400 mg and 200 mg...
January 20, 2024: Clinical Pharmacokinetics
https://read.qxmd.com/read/38242689/ribociclib-induced-cutaneous-adverse-events-in-metastatic-hr-her2-breast-cancer-incidence-multidisciplinary-management-and-prognostic-implication
#29
JOURNAL ARTICLE
Riccardo Giovanni Borroni, Michela Bartolini, Mariangela Gaudio, Flavia Jacobs, Chiara Benvenuti, Riccardo Gerosa, Paola Tiberio, Sofia Ada Assunta Maria Manara, Alessandra Solferino, Armando Santoro, Rita De Sanctis
BACKGROUND: Ribociclib is approved for hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC) treatment, in combination with endocrine therapy. Hematological, hepatic, and cardiac adverse events (AEs) emerged from pivotal trials, but little is known about cutaneous adverse events (CAEs). PATIENTS AND METHODS: We report data from a retrospective cohort study of all patients with HR+/HER2- ABC treated with ribociclib at Humanitas Cancer Center between June 2017 and December 2022...
January 18, 2024: Oncologist
https://read.qxmd.com/read/38239070/insightful-t-sne-guided-exploration-spotlighting-palbociclib-and-ribociclib-analogues-as-novel-wee1-kinase-inhibitory-candidates
#30
JOURNAL ARTICLE
Rajesh Muthuraj, Dhanushya Gopal, Iqrar Ahmed, Jaikanth Chandrasekaran
In the era of targeted therapeutics, protein kinases like WEE1 have become pivotal drug targets, especially for cancer therapy. Utilizing a multi-faceted approach, our study adds fresh insights to this endeavour. We employed the t-SNE algorithm, combined with ECFP4 fingerprints, to analyse the molecular similarity between FDA-approved drugs and known clinical trial inhibitors. Our t-SNE analysis identified the closest clusters to known inhibitors and selected 11 FDA-approved drugs for further study. Using the DrugSpaceX platform, we generated analogues for these 11 FDA-approved drugs...
January 18, 2024: Journal of Biomolecular Structure & Dynamics
https://read.qxmd.com/read/38224427/multi-center-retrospective-review-of-vitiligo-like-lesions-in-breast-cancer-patients-treated-with-cyclin-dependent-kinase-4-and-6-inhibitors
#31
JOURNAL ARTICLE
Alexander S Bang, Christopher J Fay, Nicole R LeBoeuf, Farshid Etaee, Jonathan S Leventhal, Vincent Sibaud, Joshua Arbesman, Jennifer Y Wang, Bernice Y Kwong
PURPOSE: Cutaneous adverse effects from cyclin-dependent 4 and 6 kinase inhibitors (CDK4/6i) used in metastatic breast cancer are prevalent and well described. Vitiligo-like lesions have been reported and are rare. They can negatively impact patients' quality of life and may be associated with survival benefits. We describe the clinical characteristics of vitiligo-like lesions in an international cohort of patients treated with CDK4/6i to help improve recognition and management. METHODS: Retrospective review of patients diagnosed with vitiligo-like lesions from CDK4/6i from five academic institutions in the USA and Europe was performed...
January 15, 2024: Breast Cancer Research and Treatment
https://read.qxmd.com/read/38212842/a-network-meta-analysis-of-efficacy-and-safety-for-first-line-and-second-further-line-therapies-in-postmenopausal-women-with-hormone-receptor-positive-her2-negative-advanced-breast-cancer
#32
JOURNAL ARTICLE
Hanqiao Shao, Mingye Zhao, Ai-Jia Guan, Taihang Shao, Dachuang Zhou, Guo Yu, Wenxi Tang
BACKGROUND: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR + /HER2 -) advanced breast cancer is a prevalent subtype among postmenopausal women. Despite the growing number of randomized clinical trials (RCTs) exploring this topic, the efficacy and safety of first-line and second/further-line treatments remain uncertain. Accordingly, our aim was to conduct a comprehensive evaluation of the efficacy and safety of these therapies through network meta-analysis...
January 12, 2024: BMC Medicine
https://read.qxmd.com/read/38161904/a-rare-presentation-of-metastatic-breast-cancer-manifesting-as-diffuse-nodular-skin-lesions
#33
Henrik Ghantarchyan, Nia Abbas, Azaria Lewis, Christopher Chamanadjian, Raoufi Kambiz
We present a 63-year-old African American female with a prior medical history of gastroesophageal reflux disease (GERD) and uterine fibroids whose primary concern was vaginal bleeding. She had no prior medical care established, and the last mammogram was conducted 10 years prior with normal results. She has had multiple ED visits for symptoms of reflux and vaginal bleeding and has been discharged with a primary care follow-up referral each time. On physical exam, there was evidence of nodular skin lesions, tightening of the skin on her face, neck, and back, as well as nodular skin lesions on her neck, back, chest, and abdomen, notably progressing in number, not in size, in a caudal fashion...
November 2023: Curēus
https://read.qxmd.com/read/38154393/efficacy-safety-and-prognosis-prediction-in-patients-treated-with-ribociclib-in-combination-with-letrozole-final-results-of-phase-3b-ribecca-study-in-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-locally-advanced-or-metastatic
#34
MULTICENTER STUDY
Peter A Fasching, Thomas Decker, Andreas Hartkopf, Arnd Nusch, Bernhard J Heinrich, Christian Kurbacher, Roswitha Fuchs, Hans Tesch, Petra Krabisch, Jens Huober, Sherko Kuemmel, Sara Brucker, Wolfgang Janni, Andreas Schneeweiss, Martin Schuler, Tanja Fehm, Diana Lüftner, Claudia Quiering, Claudia Voges, Julia Kreuzeder, Mattea Reinisch
BACKGROUND: In MONALEESA-2, addition of ribociclib to letrozole resulted in significantly longer progression-free survival (PFS) in postmenopausal women with HR+HER2- advanced breast cancer (ABC). RIBociclib for the treatment of advanCed breast CAncer (RIBECCA) study investigated ribociclib plus letrozole in a patient population reflecting routine clinical practice. PATIENTS AND METHODS: In this multicenter, open-label, single-arm, phase 3b study, patients with HR+HER2- ABC not amenable to curative therapy and ECOG performance status ≤ 2 received ribociclib plus letrozole (cohort A: postmenopausal women and men in first-line; cohort B: pre-/perimenopausal women in first-line [B1], patients pretreated for advanced disease [B2])...
February 2024: European Journal of Cancer
https://read.qxmd.com/read/38127209/targeted-delivery-of-liposomal-ribociclib-to-slc7a5-transporters-in-breast-cancer-cells
#35
JOURNAL ARTICLE
Mahtab Afsharzadeh, Jaleh Varshosaz, Mina Mirian, Farshid Hasanzadeh
This study aimed to prepare SLC7A5 transporters targeted liposomes of Ribociclib (RB) by stear(o)yl conjugation of Phe, Asp, Glu amino acids to liposomes as targeting moieties. The liposomes were optimized for their formulations. Cell analysis on two cell lines of MCF-7 and NIH-3T3 were done including; cell viability test by MTT assay, cellular uptake, and cell cycle arrest by flow cytometry. The optimal liposomes showed the particle size of 123.6 ± 1.3 nm, drug loading efficiency and release efficiency of 83...
December 21, 2023: Investigational New Drugs
https://read.qxmd.com/read/38112006/adjuvant-treatment-in-hormone-receptor-positive-early-breast-cancer-new-approaches-of-endocrine-therapy
#36
REVIEW
Simone Nardin, Tommaso Ruelle, Irene Giannubilo, Lucia Del Mastro
Breast cancer is the most common cancer in women, and luminal breast cancer is the predominant subtype, characterized by the presence of estrogen receptors and/or progesterone receptors in tumor cells. Adjuvant endocrine therapy is the pivotal approach in the management of luminal early breast cancer. Hence, new therapeutic approaches have been studied during the last few years, especially in patients with high risk of recurrence.Here we provide a summary of the most recent clinical trials evaluating adjuvant treatment in hormone-receptors-positive early breast cancer...
December 19, 2023: Tumori
https://read.qxmd.com/read/38110309/-consensus-on-the-clinical-use-of-cdk4-6-inhibitors-for-the-treatment-of-hormone-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-breast-cancer-2023-edition
#37
JOURNAL ARTICLE
(no author information available yet)
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have led transformative breakthrough of clinical therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER-2)-negative breast cancer patients. CDK4/6 inhibitors that have been marketed in China include Ribociclib, Palbociclib, Abemaciclib and Dalpiciclib. For HR-positive HER-2-negative locally advanced and metastatic breast cancer, CDK4/6 inhibitors combined with endocrine therapy have become standard regimen, which can prolong the survival of patients...
December 23, 2023: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://read.qxmd.com/read/38107828/matching-adjusted-indirect-comparison-of-pfs-and-os-comparing-ribociclib-plus-letrozole-versus-palbociclib-plus-letrozole-as-first-line-treatment-of-hr-her2-advanced-breast-cancer
#38
JOURNAL ARTICLE
Komal Jhaveri, Joyce O'Shaughnessy, Peter A Fasching, Sara M Tolaney, Denise A Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S Rugo
BACKGROUND: Current standard-of-care first-line treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) is cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + endocrine therapy. In the MONALEESA-2 trial, first-line ribociclib + letrozole demonstrated statistically significant overall survival (OS) benefit versus placebo + letrozole in postmenopausal patients with HR+/HER2- ABC. In the PALOMA-2 trial, first-line palbociclib + letrozole did not show OS benefit versus placebo + letrozole in a similar patient population...
2023: Therapeutic Advances in Medical Oncology
https://read.qxmd.com/read/38107071/ribociclib-induced-liver-injury-a-case-report
#39
Sofia Schaeffer, Christian Lutz, Michael Dobbie, Luigi M Terracciano, Matthias Matter, Jürg Vosbeck, Markus H Heim, Christine Bernsmeier
BACKGROUND: Idiosyncratic drug-induced liver injury (DILI) is a rare, unpredictable hepatic adverse event and the most common cause of acute liver failure in Europe and the US. Ribociclib is a potent Cyclin-dependent kinase 4 and 6 (CDK4/6)-inhibitor administered for advanced hormone-receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Previous reports have shown hepatotoxicity without liver necrosis related to ribociclib. CASE PRESENTATION: A 41-year-old female patient with primary metastatic HR-positive, HER2-negative breast cancer developed liver enzyme elevation under treatment with ribociclib...
2023: Frontiers in Oncology
https://read.qxmd.com/read/38102891/first-line-cdk4-6-inhibitor-based-combinations-for-hr-her2-advanced-breast-cancer-a-bayesian-network-meta-analysis
#40
REVIEW
Xianan Guo, Yunxiang Zhou, Kun Zhang, Wei Lu, Xi Zhong, Shijie Wu, Lu Shen, Huihui Chen, Yiding Chen
BACKGROUND: International guidelines recommend cyclin-dependent kinase 4/6 inhibitor (CDK4/6i)-based first-line therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, direct drug comparisons are lacking. We aimed to identify the most effective and safe therapy through network meta-analysis (NMA). METHODS: We searched PubMed, Embase, Web of Science, Cochrane Central Register of Controlled Trials, and OpenGrey up to September 30, 2023...
December 16, 2023: Journal of Evidence-based Medicine
keyword
keyword
96145
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.